Xtandi seeks first-line status

Share this article:

The FDA gave Medivation and Astellas a boost by giving priority review to the partners' application to expand the prostate cancer drug's indication to include first-line status.

The drug is currently indicated for metastatic castration-resistant prostate cancer patients who have previously undergone chemotherapy and was approved in 2012.

PM Live notes that a pre-chemo indication will allow Medivation to provide early treatment competition for Janssen's prostate cancer drug Zytiga, which lassoed the pre-chemo approval in July 2013.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.